Aptamer and Timser Partnership
|
|
22 May 2024 |
|
|
|
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer and Timser partner to deliver world's first blood test for cervical cancer
Agreement for up to £465,000 signed for Optimer development
Optimer binders will be developed for use in a cervical cancer blood test
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women's health, with a deal value of up to £465,000.
Under the terms of the agreement, Aptamer Group will develop Optimer binders to Timser's patented cervical cancer biomarker panel - a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world's first blood test for cervical cancer, preventing invasive smear tests and delivering earlier, more sensitive diagnostics.
Pairs of Optimer binders will be developed to each of the three biomarker proteins that form the unique cervical cancer signature. Timser will receive a licence for the use of the Optimers in its specific test combination, which is patented in 21 countries, including the USA.
Cervical cancer is the fourth most common cancer type in women worldwide. Present screening methods rely on invasive and relatively low sensitivity Papanicolaou (PAP) smear tests. The Optimer enabled Timser's diagnostic will allow earlier detection at the precancerous lesion stage, which is associated with increased survival. Use of a blood-based test over traditional PAP smears will offer the potential for increased detection rates by improving uptake due to the less invasive testing method.
As Timser expands its diagnostic tests into diverse markets, including low-income countries, the Optimer binders offer advantages to support continued supply and quality. With superior shelf-life and enhanced temperature stability compared to antibodies, Optimer binders facilitate global test distribution without compromising quality or performance. Previous attempts by Timser to develop antibodies to support the test have failed due to issues with antibody batch variability and supply chains. Unlike antibodies, Optimer binders are chemically manufactured, giving consistent quality, with the potential to use multiple manufacturers both locally and globally to prevent supply chain issues.
Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests."
Mercedes Gutierrez, Chief Executive Officer of TIMSER Group: "We are equally excited about this collaboration with Aptamer Group. The potential of Optimer binders to enhance the accuracy and reliability of our cancer diagnostics tests is truly promising. By integrating this advanced technology, we are confident in our ability to overcome the limitations of traditional antibodies and improve the outcomes for patients undergoing cervical cancer screening. We look forward to a successful partnership and to witnessing the impact that this new technology will have for women across the globe."
- ENDS -
For further information, please contact:
|
Aptamer Group plc Steve Hull |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.
About TIMSER GROUP
Timser Group is a pioneering organization dedicated to the advancement of women's healthcare through innovative scientific solutions. The company focuses on developing diagnostic tests and treatments that address critical health issues, particularly those affecting women. Timser Group operates specialized laboratories, including clinical and research labs, which are instrumental in their groundbreaking work on cervical cancer diagnostics and other health conditions.
TIMSER Group holds several patents in over 20 countries that are the product of extensive research and development efforts in various fields, particularly in women's healthcare and pharmaceutical innovations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund